Objectives: To measure the levels of serum CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in patients with ovarian cancer (OvCa), benign gynecological conditions and healthy women and in a number of other cancer types (breast, colorectal, lung, prostate and testicular).
Introduction
Ovarian cancer (OvCa) occurs in 1 of 2500 postmenopausal women in North America and is the most lethal gynecological malignancy. When OvCa is diagnosed at early stages, the 5-year survival rate is close to 90% [1] , however, the vast majority of patients are identified when they have late stage disease where overall 5-year survival is 10-30% [2, 3] . Unfortunately, other than definitive diagnosis by invasive surgery (laparoscopy or laparotomy), which carries its own morbidity and mortality, no diagnostic or screening test is presently suitable for the early diagnosis of ovarian carcinoma. Current screening modalities include pelvic examination, ultrasonography, and serum tumor markers [4] . Biannual pelvic examination, either during a routine physical examination or during evaluation of nonspecific abdominal/pelvic discomfort rarely detects early stage OvCa and therefore, has little impact on reducing cancer mortality. While it remains important in the assessment of women presenting with gynecological symptoms, it cannot be recommended as a first-line screening tool. Similarly, although transvaginal ultrasound is highly accurate in both the detection and the morphologic characterization of adnexal masses, the test's ability to distinguish benign from malignant disease is more problematic [5] .
The ability to detect human malignancy via a simple blood test has long been an objective in medical screening. The advantages of such an easy to use, relatively noninvasive and operator-independent test are self-evident. A variety of ovarian tumor markers have been studied. The most extensively investigated of these is carbohydrate antigen 125 (CA125), a large glycoprotein of unknown function and an FDAapproved serum marker for monitoring OvCa recurrence. Unfortunately, CA 125 lacks sufficient sensitivity as it is not elevated in 20-30% of patients with advanced disease [6] and serum levels are within the normal range in 50% of women with surgically documented stage I disease [7] . CA 125 also demonstrates poor specificity as it is elevated during menstruation or pregnancy and in other benign conditions such as endometriosis, peritonitis, or cirrhosis, particularly with ascites [8] . A major unmet need is the discovery of novel serological biomarkers to diagnose OvCa early so that they will have a strong impact on improving patient outcome through the administration of potentially curative surgery and/or treatment. Our laboratory has recently published a study where we mined publicly-available bioinformatic databases, in order to identify genes that were either uniquely, or highly expressed in one or two tissues (as opposed to genes that are ubiquitously expressed in many tissues) [9] . CUZD1 (CUB and zona pellucida-like domain-containing protein 1) was identified in this study as being pancreas-specific. Our laboratory has documented that CUZD1 is a novel pancreatic cancer serum biomarker (Chrystoja et al., manuscript in preparation). To date, there are only a handful of studies published in the literature related to CUZD1. Also called Transmembrane protein UO-44, the gene is located on chromosome 10q26.13 and encodes a 607 amino acid trans-membrane protein. In 2001, Huynh et al. isolated a uterine and ovarian specific, tamoxifen and estrogen-induced rat UO-44 cDNA through differential display and cDNA library screening [10] . The authors found that the UO-44 gene was observed only in the uterus and ovary of rats. In 2004, the same group reported the cloning and characterization of four novel splice variants of the human ortholog of UO-44 (HuUO-44) [11] . While the authors found in 2001 that the Rat UO-44 was highly expressed in the ovaries and uterus, the human ortholog HuUO-44 was found highly expressed in the pancreas. The addition of HuUO-44 antisera markedly inhibited the NIH-OVCAR3 ovarian cancer cell attachment and proliferation. Hence, the authors postulated that HuUO-44 may be involved in ovarian cancer cell attachment and proliferation. In 2007, Leong et al. observed that the overexpression of HuUO-44 in ovarian cancer cells significantly conferred resistance to cisplatin [12] .
Taken together, all studies related to CUZD1/UO-44 suggest that it is a transmembrane-associated protein, expressed in the uterus, ovaries and pancreas. Primary translation products of UO-44 gene encode a polypeptide of 607 amino acids, which contains a secretory signal sequence, two CUB domains, a zona pellucida domain and a transmembrane region [13] . To date, no data exists examining the levels of CUZD1/UO-44 in the blood of ovarian cancer patients (or other cancer types) to determine if it has diagnostic potential. In this study, we investigated the serum levels of CUZD1 in healthy controls and ovarian cancer patients, as well as in other cancer types including breast, colorectal, lung, prostate and testicular. Herein, we report significantly elevated levels of CUZD1 in the serum of ovarian cancer patients, supporting CUZD1 as a novel serum biomarker for ovarian cancer. The protein is also elevated in lung and breast cancer patients.
Materials and methods

Patients and specimens
Preliminary verification study was performed using sera from 20 confirmed late stage (III-IV) epithelial ovarian cancer cases, 11 breast, 10 colorectal, 10 lung, 15 prostate and 10 testicular cancer cases (of unknown stage) from Toronto, Canada. The control cohort consisted of 9 men and 9 women with no previous history of malignancy. For the OvCa validation study, an independent cohort of samples was used (n= 18 late stage OvCa patients, 8 benign gynecological conditions and 8 healthy women) which were analyzed on a different day. All samples were collected and stored in an identical fashion (−80°C) until analysis. Samples were collected with informed consent and Institutional Review Board approval.
Measurement of CUZD1 and CA125 in serum
Using a commercially available sandwich ELISA assay from USCN LifeSciences, Missouri City, USA for CUZD1, the levels of this protein in serum were measured in duplicate for all specimens, as per the manufacturer's recommendations. Briefly, pre-coated polystyrene strips were loaded with 100 μL of serum or standards and incubated for 2 h at 37°C with gentle shaking. After washing the strips, 100 μL of 'detection reagent A' was added and the strips were incubated for an additional hour at 37°C with gentle shaking. After washing, 100 μL of 'detection reagent B' was added and the strips were incubated for 30 min at 37°C with gentle shaking. After a final washing, 100 μL of 3,3,5,5′-tetramethylbenzidine substrate solution was added and the strips were incubated for 15 min at 37°C with gentle shaking. The chromogenic reaction was stopped with the addition of 50 μL of hydrochloric acid solution. Absorbance was measured with the Wallac EnVision 2103 Multilabel Reader (Perkin Elmer) at 450 nm standardized to background absorbance at 620 nm. CA 125 levels were measured using the Roche Elecsys automated ELISA platform. All serum samples for CA125 and CUZD1 analysis were diluted 5-fold (or more) with 60 g/L of bovine serum albumin before analysis. Final concentrations were calculated by multiplying with the dilution factor.
Data analysis and statistics
Statistical analysis was performed using SPSS software, version 15.0 (SPSS Inc., Chicago, IL). Normal distribution was evaluated using Shapiro-Wilk test and by inspection of the Q-Q plot. A KruskalWallis test was performed for comparison between more than two groups and a Mann-Whitney U test with Bonferroni's correction was performed for comparison between two groups. A p-value less than 0.05 was considered to be statistically significant. Spearman's rank correlation coefficient was used to assess the correlations among CUZD1 and CA125 (GraphPad Software Inc., La Jolla, CA).
Results
Increased serum CUZD1 and CA125 in ovarian cancer patients
In the initial evaluation, CUZD1 displayed significant discriminatory power (pb 0.00001) between 9 healthy women and 20 late stage OvCa patients. The distribution of CUZD1, as measured by ELISA, in cases and controls are shown in Fig. 1A . Serum CUZD1 was significantly elevated in ovarian cancer (mean± standard deviation) compared to healthy controls (334±183 μg/L vs. 1.6± 0.7 μg/L), as was serum CA125 (1565± 1388 U/mL vs. 12± 5.2 U/mL; p b 0.001). The specific serum biomarker levels for these samples are highlighted in Table 1 .
For CUZD1, median values of 1.7 μg/L and 300 μg/L were observed for healthy controls and ovarian cancer cases, respectively, with a median control:case ratio of 174. Mean values of 1.6 μg/L and 334 μg/L were also observed for healthy controls and ovarian cancer cases, respectively, with a mean control:case ratio of 207. For CA125, median values of 13 U/mL and 1388 U/mL were observed for healthy controls and ovarian cancer cases respectively, with a median control:case ratio of 107. Mean values of 12 U/mL and 1565 U/mL were also observed for healthy controls and ovarian cancer cases respectively, with a mean control:case ratio of 130. The differences in median values between OvCa cases and controls for both CUZD1 and CA125 were highly significant by the Mann-Whitney U test (p b 0.001).
Serum CUZD1 was found to be significantly correlated with serum CA125 in the 20 ovarian cancer patients (Fig. 2) . The Spearman correlation coefficient between CUZD1 and CA125 was 0.90 (95% confidence interval of 0.75-0.96; p b 0.0001).
CUZD1 levels were further measured in an independent cohort of 18 late stage OvCa patients (mean ± standard deviation of CA125 = 1329 ± 380 U/mL), 8 benign conditions (CA125 b 35 U/mL) and 8 healthy women (CA125 b 35 U/mL). Fig. 1B shows the raw absorbance readings at 450 nm, corrected for background at 620 nm from an ELISA plate for these samples. It is evident that the wells containing the 18 OvCa samples have values well above the highest standard in the calibration curve (>20 μg/L). Therefore, the respective CUZD1 concentrations in these OvCa specimens are much higher than 100 μg/L (specimens were diluted 1:5 prior to loading on the wells; similar data to the preliminary verification study). The specimens corresponding to the 8 benign conditions and 8 normal controls had mean CUZD1 levels of b1 μg/L. The results shown in Fig. 1 , with a combined group of 38 late stage ovarian cancer patients and 25 non-cancer patients, confirm that CUZD1 has a very powerful discriminatory power between normal/benign and late stage OvCa patients.
Serum levels of CUZD1 in other cancer types CUZD1 levels were examined in the serum of 5 other cancer types (breast, colorectal, lung, prostate and testicular) along with normal male (n = 9) and female (n = 9) sera. Fig. 3 displays a scatter plot of the values obtained for CUZD1. Sera from both breast cancer and lung cancer displayed higher levels of CUZD1 than the other 3 cancer types. The differences between lung cancer and male and female controls were significant by the Kruskal-Wallis test (p = 0.0025) but the differences between breast cancer patients and female controls were not significant (p > 0.05).
Discussion
The precise function and biological relevance of CUZD1 to ovarian cancer remain largely unknown. The limitations of CA125 as a diagnostic marker are well described and the need to identify a novel biomarker is well appreciated in the clinical community. In this study, we report for the first time elevated CUZD1 levels in the serum of ovarian cancer patients, as well as in breast and lung cancer patients.
Our data provides strong evidence that CUZD1 represents a novel serological marker for ovarian cancer as this marker performed equally as well as CA125 in two independent cohorts of samples consisting of healthy controls and ovarian cancer cases. More studies on this highly promising biomarker are warranted. Whether CUZD1 has the ability to act as a diagnostic, prognostic, predictive, or therapeutic tool remains to be seen as validation in larger cohorts are needed to confirm the clinical utility of this marker. It will be particularly interesting to evaluate CUZD1 levels in early stage and prediagnostic serum samples from ovarian cancer patients.
